ClinicalTrials.gg
RecruitingNCT07741461Updated Aug 17, 2026

ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

A Phase 1 interventional study of ACT201 Injection and ACT201 Injection Placebo in Chronic Hepaititis B, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical trial consisting of two parts. Part 1 includes single ascending dose (SAD) and multiple ascending dose (MAD) cohorts conducted in healthy participants. Part 2 is a multiple ascending dose (MAD) trial enrolling HBeAg-negative chronic hepatitis B (CHB) participants with suppressed HBV DNA under stable nucleos(t)ide analog (NA) therapy.

02

Conditions studied

  • Chronic Hepaititis B

Keywords

  • Chronic Hepaititis B
  • ACT201 Injection
03

In context

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 33 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  • Participants fully understand the purpose, nature and methods of the trial as well as potential adverse events, voluntarily participate in this trial and provide written ;
  • Aged between 18 and 55 years old (inclusive) at the time of informed consent, male or female;
  • meets specified criteria;
  • Physical examination, vital signs, laboratory tests, and imaging examinations at screening are normal or abnormalities are considered clinically insignificant;
  • Participants (including their partners) are willing to use effective measures from screening through 6 months after the last administration of product, with no plans for pregnancy, sperm donation or oocyte donation.

Part 2:

  • Participants fully understand the purpose, nature and methods of the trial as well as potential adverse events, voluntarily participate in this trial and provide written informed consent;
  • Aged between 18 and 65 years old (inclusive) at the time of informed consent, male or female;
  • Body mass index meets specified criteria;
  • -positive or HBV DNA-positive for at least 6 months, or previous liver confirming chronic HBV infection;
  • Receiving stable nucleos(t)ide analogue (NA) therapy at screening, with no planned changes to NA regimen during the trial;
  • Serum ≤ 2 × at screening; HBeAg, HBV DNA and HBsAg levels meet protocol-specified criteria;
  • Participants (including their partners) are willing to use effective contraceptive measures from screening through 6 months after the last administration of investigational product, with no plans for pregnancy, sperm donation or oocyte donation.

Exclusion criteria

Exclusion Criteria:

Part 1:

  • Known or suspected to ACT201 or its ; or participants with allergic diathesis (multiple drug and food allergies judged by the Investigator).
  • History of clinically significant diseases involving cardiovascular, hematologic and lymphatic, urinary, endocrine, immune, psychiatric, or nervous systems (e.g., epilepsy).
  • Vital signs or laboratory examinations at screening meet the exclusion cut-off values specified in the protocol.
  • Use of any prescription drugs, over-the-counter medications, vitamin products or herbal medicines within 2 weeks prior to the first dose (topical medications with local effects are excluded).
  • Positive , hepatitis B core antibody, antibody, antibody, or Treponema pallidum antibody at screening.
  • interval (QT corrected by Fridericia's formula) > 450 ms at screening.
  • Daily cigarette consumption exceeding 5 cigarettes within 3 months before screening.
  • History of drug abuse or illicit drug use within 1 year before screening, or positive urine drug screen at screening.
  • History of alcohol abuse within 6 months before screening (14 alcohol units per week: 1 unit = 285 mL beer with \~3.5% alcohol, or 25 mL spirits with \~40% alcohol, or 100 mL wine with \~10% alcohol), or positive breath alcohol test at screening.
  • Vaccination administered within 1 month before screening, or planned vaccination during the trial period.
  • Blood loss or blood donation ≥ 400 mL within 3 months before screening (menstrual bleeding in female participants excluded), or planned blood donation during the trial period.
  • Female participants who are breastfeeding or have a positive serum pregnancy test at screening.
  • Participation in any clinical trial with an medicinal product/investigational device within 3 months before screening or within 5 half-lives (whichever is longer).
  • Any other condition deemed unsuitable for trial participation by the Investigator.

Part 2:

  • Major trauma or major surgery within 3 months before screening; or planned surgery during the trial period that may impair trial compliance or safety assessment as assessed by the Investigator.
  • Uncontrolled and clinically significant abnormalities other than chronic HBV infection, such as acute cerebrovascular disease, severe or unstable cardiac disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled dyslipidemia, etc.
  • History of other clinically significant liver diseases.
  • History of liver cirrhosis or progressive liver fibrosis; or liver stiffness measurement (LSM) ≥ 8.5 kPa at screening.
  • Alpha-fetoprotein > 50 ng/mL, or imaging suggestive of possible malignant hepatic lesions.
  • Past or current manifestations of hepatic decompensation.
  • History of extrahepatic diseases potentially related to HBV immune status.
  • History of vasculitis; or signs/symptoms suggestive of underlying vasculitis; or past/current other diseases potentially associated with vasculitic disorders.
  • Active infection requiring systemic antiviral or antibacterial treatment at screening, excluding HBV infection.
  • History of malignant tumors within 5 years before screening, except for specific curable cancers resected surgically.
  • Prior solid organ or bone marrow transplantation.
  • Use of systemic within 3 months before the first dose of investigational product [short-term (≤7 days) for prophylaxis or treatment of non- diseases excluded]; use of immunomodulators or cytotoxic agents within 6 months before the first dose of investigational product.
  • Receipt of any oligonucleotide or small interfering RNA (siRNA) therapy within 12 months before the first dose of investigational product.
  • Coexisting indication for anticoagulant therapy or anticipated requirement for anticoagulation during the trial.
  • Any of the following laboratory results at screening, or other clinically significant abnormalities rendering the participant unsuitable for trial participation:

count \< 125 × 10\^9/L \< 1.5 × 10\^9/L \< 100 g/L Total > 1.25 × Serum albumin \< 35 g/L Estimated (eGFR) \< 60 mL/min/1.73 m\^2 (calculated using the CKD-EPI formula) international normalized ratio (INR) > 1.25 Positive hepatitis C antibody, human immunodeficiency virus antibody, or Treponema pallidum antibody

  • QTcF interval (QT corrected by Fridericia's formula) > 450 ms at screening, or other clinically significant abnormalities identified at screening.
  • Known or suspected hypersensitivity to ACT201 or its excipients; or participants with allergic diathesis (multiple drug and food allergies judged clinically significant by the Investigator).
  • Daily cigarette consumption exceeding 5 cigarettes within 3 months before screening.
  • History of drug abuse or illicit drug use within 1 year before screening, or positive urine drug screen at screening.
  • History of alcohol abuse within 6 months before screening, or positive breath alcohol test at screening.
  • Vaccination administered within 1 month before screening, or planned vaccination during the trial period.
  • Blood loss or blood donation ≥ 400 mL within 3 months before screening (menstrual bleeding in female participants excluded), or planned blood donation during the trial period.
  • Female participants who are breastfeeding or have a positive serum pregnancy test at screening.
  • Participation in any clinical trial with an investigational medicinal product/investigational device within 3 months before screening or within 5 half-lives (whichever is longer).
  • Any other condition deemed unsuitable for trial participation by the Investigator.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    ACT201 Injection group

    Drug: ACT201 Injection

  • Placebo comparator
    ACT201 Injection Placebo

    Drug: ACT201 Injection Placebo

Interventions

  • Part 1 SAD (Single Ascending Dose): Single-dose subcutaneous injection per assigned dose group. Part 1 MAD (Multiple Ascending Dose) and Part 2: Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

  • DrugACT201 Injection Placebo

    Part 1 SAD (Single Ascending Dose): Single-dose subcutaneous injection administered per assigned dose group. Part 1 MAD (Multiple Ascending Dose) and Part 2: Subcutaneous injection administered per assigned dose group; the treatment duration shall comply with the study protocol.

06

What researchers measure

Primary outcomes

  1. Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results.

    Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs).

    Time frame: throughout the full study period,an average of 4 months

Secondary outcomes

  1. Plasma drug concentrations in healthy participants and participants withCHB

    Time frame: throughout the full study period,an average of 4 months

  2. Area Under the Concentration-Time Curve from time zero to the last measurable concentration(AUC₀-ₜ)

    Time frame: throughout the full study period,an average of 4 months

  3. Area Under the Concentration-Time Curve from time zero to infinity(AUC₀-∞)

    Time frame: throughout the full study period,an average of 4 months

  4. Apparent Volume of Distribution(Vd/F)

    Time frame: throughout the full study period,an average of 4 months

  5. First-order Elimination Rate Constant(Kel)

    Time frame: throughout the full study period,an average of 4 months

  6. Elimination Half-life(t₁/₂)

    Time frame: throughout the full study period,an average of 4 months

  7. Mean Residence Time(MRT)

    Time frame: throughout the full study period,an average of 4 months

  8. Apparent Clearance(CL/F)

    Time frame: throughout the full study period,an average of 4 months

  9. Minimum Plasma Concentration at Steady State(Cₘᵢₙ,ₛₛ)

    Time frame: throughout the full study period,an average of 4 months

  10. Maximum Plasma Concentration at Steady State(Cₘₐₓ,ₛₛ)

    Time frame: throughout the full study period,an average of 4 months

  11. Average Plasma Concentration at Steady State(Cₐᵥ,ₛₛ)

    Time frame: throughout the full study period,an average of 4 months

  12. Area Under the Concentration-Time Curve over one dosing interval at steady state(AUC₀-τ)

    Time frame: throughout the full study period,an average of 4 months

  13. Degree of Fluctuation (DF)

    Time frame: throughout the full study period,an average of 4 months

  14. Accumulation Factor (Rac)

    Time frame: throughout the full study period,an average of 4 months

  15. Urinary Concentration

    Time frame: throughout the full study period,an average of 4 months

  16. Cumulative Amount Excreted in Urine

    Time frame: throughout the full study period,an average of 4 months

  17. Cumulative Percentage of Dose Excreted in Urine

    Time frame: throughout the full study period,an average of 4 months

  18. Renal Clearance(CL)

    Time frame: throughout the full study period,an average of 4 months

  19. HBsAg and HBsAb levels and changes from baseline among participants with CHB

    Time frame: throughout the full study period,an average of 4 months

  20. HBsAg seroclearance rate among participants with CHB

    Time frame: throughout the full study period,an average of 4 months

  21. HBsAg seroconversion rate among participants with CHB

    Time frame: throughout the full study period,an average of 4 months

  22. Placebo-corrected baseline-adjusted ΔQTc (ΔΔQTc) among healthy participants

    Time frame: throughout the full study period,an average of 4 months

  23. Anti-drug antibody (ADA) positive rate among healthy participants and participants with CHB

    Time frame: throughout the full study period,an average of 4 months

  24. Antibody titers among healthy participants and participants with CHB

    Time frame: throughout the full study period,an average of 4 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Aug 3, 2026
StartActual
Aug 6, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07741461
Collaborators
Huashan Hospital
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Aug 6, 2026
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Jing Zhang, Ph.D.
Contact
Zhangj_fudan@163.com
021-52887926
Wenhong Zhang, Ph.D.
Contact
zhangwenhong@fudan.edu.cn
18121186602
Jing Zhang, Ph.D.
principal investigator · Huashan Hospital
Wenhong Zhang, Ph.D.
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ACT201

Start the discussion